Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
J Virol ; 97(1): e0146722, 2023 01 31.
Article in English | MEDLINE | ID: mdl-36475768

ABSTRACT

Assembly of the adenovirus capsid protein hexon depends on the assistance of the molecular chaperone L4-100K. However, the chaperone mechanisms remain unclear. In this study, we found that L4-100K was involved in the hexon translation process and could prevent hexon degradation by the proteasome in cotransfected human cells. Two nonadjacent domains, 84-133 and 656-697, at the N-terminal and C-terminal regions of human adenovirus type 5 L4-100K, respectively, were found to be crucial and cooperatively responsible for hexon trimer expression and assembly. These two chaperone-related domains were conserved in the sequence of L4-100K and in the function of hexon assembly across different adenovirus serotypes. Different degrees of cross-activity of hexon trimerization with different serotypes were detected in subgroups B, C, and D, which were proven to be controlled by the interaction between the C-terminal chaperone-related domain of L4-100K and hypervariable regions (HVR) of hexon. Additionally, HVR-chimeric hexon mutants were successfully assembled with the assistance of the 1-697 mutant. Structural analysis of 656-697 by nuclear magnetic resonance and structural prediction of L4-100K using Robetta showed that the two conserved domains are mainly composed of α-helices and are located on the surface of the highly folded core region. Our research provides a more complete understanding of hexon assembly and guidance for the development of hexon-chimeric adenovirus vectors that will be safer, smarter, and more efficient. IMPORTANCE Adenovirus vectors have been widely used in clinical trials of vaccines and gene therapy, although some deficiencies remain. Chimeric modification of the hexon was expected to improve the potency of preexisting immune evasion and targeting, but in many cases, viral packaging is prevented by the inability of the chimeric hexon to assemble correctly. So far, few studies have examined the mechanisms of hexon trimer assembly. Here, we show how the chaperone protein L4-100K contributes to the assembly of the adenovirus capsid protein hexon, and these data will provide a guide for novel adenovirus vector design and development, as we desired.


Subject(s)
Adenoviruses, Human , Molecular Chaperones , Viral Nonstructural Proteins , Humans , Adenoviruses, Human/genetics , Adenoviruses, Human/metabolism , Capsid/metabolism , Capsid Proteins/metabolism , Molecular Chaperones/genetics , Molecular Chaperones/metabolism , Viral Nonstructural Proteins/genetics , Viral Nonstructural Proteins/metabolism
2.
Zhonghua Nan Ke Xue ; 28(9): 831-836, 2022 Sep.
Article in Chinese | MEDLINE | ID: mdl-37839010

ABSTRACT

OBJECTIVE: To re-evaluate the clinical efficacy of Longjintonglin Capsules (LJTL) in the treatment of chronic prostatitis with damp-heat stasis syndrome. METHODS: This multicenter real-world study included 1 352 cases of chronic prostatitis with damp-heat and stagnation syndrome treated with LJTL (3 capsules once, tid, 30 minutes after meals, for 2 four-week courses) in addition to routine treatment. Before and after treatment, we analyzed the NIH-CPSI scores, the scores of Chinese medicine symptom quantitative classification and changes in individual symptom scores, and observed adverse reactions to medication. RESULTS: The total effectiveness rate of LJTL was 93.64%. Compared with the baseline, the NIH-CPSI scores were significantly decreased after treatment (ï¼»24.27 ± 6.04ï¼½ vs ï¼»8.17 ± 4.21ï¼½, P < 0.05), and so were the scores on the pain symptoms (ï¼»9.63 ± 3.65ï¼½ vs ï¼»3.02 ± 2.23ï¼½, P < 0.05), voiding symptoms (ï¼»5.65 ± 2.15ï¼½ vs ï¼»1.62 ± 1.36) and quality of life (ï¼»8.96 ± 2.32ï¼½ vs ï¼»3.16 ± 1.89ï¼½, P < 0.05). The effectiveness rate of LJTL was 95.9% on the Chinese medicine symptom frequent urination, 90.4% on painful urination, and 91.4% scanty dark urine, with a total effectiveness rate of 82.4% - 95.9%, all with statistically significant difference in comparison with the baseline (P < 0.05). CONCLUSION: Longjintonglin Capsules combined with routine treatment can significantly improve the clinical symptoms of chronic prostatitis with damp-heat stasis syndrome, especially effective on the symptoms of frequent urination, painful urination and scanty dark urine. Besides, it recommendable for its antidepressant and antianxiety effects, and the effect of improving the quality of life of the chronic prostatitis patients with damp-heat stasis.


Subject(s)
Drugs, Chinese Herbal , Prostatitis , Male , Humans , Drugs, Chinese Herbal/therapeutic use , Prostatitis/diagnosis , Prostatitis/drug therapy , Hot Temperature , Quality of Life , Chronic Disease , Treatment Outcome , Capsules/therapeutic use
3.
Trials ; 20(1): 446, 2019 Jul 19.
Article in English | MEDLINE | ID: mdl-31324199

ABSTRACT

BACKGROUND: Acute uncomplicated lower urinary tract infection (UTI) is one of the most common bacterial infections. Patients usually present with dysuria, urinary urgency, urinary frequency, and suprapubic pain or tenderness. Approximately 150 million people are diagnosed with UTI each year worldwide. The high recurrence rate of lower UTI is a common problem of clinical treatment. The misuse of antibiotics has led to the emergence of a number of resistant bacterial strains. Thus, traditional Chinese medicine is considered as an alternative option for treating acute uncomplicated lower UTI. Thus, this study aims to evaluate the efficacy and safety of Sanjin tablets (SJT) for the treatment of acute uncomplicated lower UTI, explore whether SJT can reduce or substitute the use of antibiotics, and reduce the recurrence rate in the treatment of acute uncomplicated lower UTI. METHODS/DESIGN: In this study, a randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical study will be established. A total of 252 patients with acute uncomplicated lower UTI (syndrome of dampness-heat in the lower jiao) will be randomly allocated in the ratio of 1:1:1 to three groups: experimental group; control group 1; and control group 2. The experimental group receives Sanjin tablets plus levofloxacin tablets (LT) placebo; the control group 1 receives LT plus SJT placebo; and the control group 2 receives SJT plus LT on the first five days, SJT plus LT placebo on the last two days. Each group will be treated for seven days and followed-up 1-2 times. The primary outcome measures of effective rate and recurrence rate are symptoms. Secondary outcome measures of effective rate and recurrence rate are the urine leukocytes, bacteriology examination, and safety assessment. Outcomes will be assessed at baseline and after treatment. DISCUSSION: This study protocol will provide the research data of efficacy and safety of SJT for the treatment of acute uncomplicated lower UTI. The first aim is to determine whether Sanjin tablets can reduce the use of antibiotics; the second aim is to determine whether Sanjin tablets can substitute the use of antibiotics. The recurrence rate will be assessed after cured to determine whether SJT can reduce the recurrence rate. The results of this study will improve the rational use of drugs, especially the rational application of antibiotics. It will also enable safety evaluation from laboratory indices and adverse events, which will provide reliable evidence for clinical treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03658291 . Registered on 4 September 2018.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Drugs, Chinese Herbal/administration & dosage , Levofloxacin/administration & dosage , Lower Urinary Tract Symptoms/drug therapy , Urinary Tract Infections/drug therapy , Administration, Oral , Adult , Anti-Bacterial Agents/adverse effects , China , Double-Blind Method , Drugs, Chinese Herbal/adverse effects , Female , Humans , Levofloxacin/adverse effects , Lower Urinary Tract Symptoms/diagnosis , Lower Urinary Tract Symptoms/microbiology , Male , Middle Aged , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Tablets , Time Factors , Treatment Outcome , Urinary Tract Infections/diagnosis , Urinary Tract Infections/microbiology , Young Adult
4.
Zhonghua Nan Ke Xue ; 25(8): 730-733, 2019 Aug.
Article in Chinese | MEDLINE | ID: mdl-32227717

ABSTRACT

OBJECTIVE: To investigate the clinical efficacy and safety of Huanshao Capsules (HSC) in the treatment of ED with spleen and kidney deficiency. METHODS: This randomized open multicentered positive drug controlled clinical trial included 248 cases of ED with spleen and kidney deficiency, which were assigned to a trial and a control group of equal number to be treated with HSC at the dose of 3 capsules tid and Wuziyanzong Pills at 6 g bid, respectively, both for 4 weeks. We recorded and compared the IIEF-5 scores, traditional Chinese medicine (TCM) symptom scores, and hepatic and renal functions between the two groups of patients before and at 2 and 4 weeks after medication. RESULTS: The clinical observation was completed in 240 of the patients. Based on the IIEF-5 scores of the patients, the total effectiveness rate was significantly higher in the trial than in the control group (76.6% vs 67.8%, P < 0.05). The TCM symptom scores were decreased by ≥95% in 14 cases (11.7%), ≥70% in 97 cases (80.8%) and ≥30% in 9 cases (7.5%) in the trial group as compared with ≥95% in 7 cases (5.8%), ≥70% in 84 cases (70.0%) and ≥30% in 29 cases (24.2%) in the control, with remarkably better improvement in the former than in the latter group (P < 0.05). Before and at 2 and 4 weeks after medication, the IIEF-5 scores were 13.04 ± 4.02, 15.95 ± 3.22 and 20.06 ± 2.17, and the TCM symptom scores were 16.64 ± 5.26, 10.08 ± 4.89 and 3.05 ± 2.18 respectively in the trial group, both significantly improved at 4 weeks in comparison with those in the control (P < 0.05). No abnormality was observed in urine and blood tests or hepatic and renal functions before and after treatment, nor obvious adverse events were found in the two groups of patients during the medication. CONCLUSIONS: Huanshao Capsules can safely and effectively improve the IIEF-5 scores and clinical symptoms of ED patients with spleen and kidney deficiency, and therefore deserve a wide clinical application.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Erectile Dysfunction/therapy , Capsules , Double-Blind Method , Humans , Kidney , Male , Medicine, Chinese Traditional , Spleen , Treatment Outcome
5.
Article in English | MEDLINE | ID: mdl-30519263

ABSTRACT

Qianlie Tongqiao Capsule (QTC) is clinically confirmed to be efficacious and safe in treating lower urinary tract syndromes and bladder dysfunction that are induced by benign prostatic hyperplasia (BPH). However, the functional mechanisms of QTC remain unclear. We aim to investigate the effects of QTC on both bladder weight and several growth factors in the bladder tissue of rats with testosterone-induced BPH. BPH in the rats was established through bilateral orchiectomy and subcutaneous administration of testosterone propionate (5 mg/kg) dissolved in corn oil. At the end of the study, all bladder tissues were collected and weighed, and a histological examination was conducted using H&E staining. Immunohistochemistry and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) were applied to detect the expression of nerve growth factor (NGF), basic fibroblast growth factor (bFGF), and transformation growth factor-ß1 (TGF-ß1) in the bladder tissue. The expression of Bcl-2 and Bax in the bladder tissue was tested by Western Blot and qRT-PCR. We found that QTC, especially when administered in high-dosages, had a significant inhibitory effect on bladder weight gain and overexpression of NGF, bFGF, and TGF-ß1 in rats with BPH. In addition, QTC downregulated and upregulated protein and mRNA expression of Bcl-2 and Bax in the bladder after prostatic obstruction, respectively. Furthermore, QTC balanced the Bcl-2/Bax ratio. Overall, these results reveal possible functional mechanisms of QTC in treating BPH-caused bladder dysfunction, and further studies are needed.

6.
Zhonghua Nan Ke Xue ; 24(1): 67-71, 2018.
Article in Chinese | MEDLINE | ID: mdl-30157364

ABSTRACT

OBJECTIVE: To observe the clinical effects of Huanshao Capsules (HSC) combined with levocarnitine (LC) on asthenospermia, oligospermia, teratozoospermia, and the semen parameters of the patients. METHODS: This randomized controlled clinical study included 186 infertility patients with spleen and kidney asthenia. We randomly divided them into three groups of equal number and treated them orally with HSC at the dose of 3 capsules tid, LC at 10 ml tid, and HSC+LC, respectively, all for 12 weeks. At 4, 8, and 12 weeks after treatment, we obtained the semen parameters from the patients and compared them among the three groups. RESULTS: Totally, 180 of the patients completed the study, 61 in the HSC, 59 in the LC and 60 in the HSC+LC group. After 12 weeks of medication, the patients of the HSC+LC group showed an increase of 42.77% in the semen volume, 142.37% in sperm concentration, 28.61% in sperm motility, and 24.39% in the percentage of grade a+b sperm and a decrease of 6.27% in the percentage of morphologically abnormal sperm as compared with the baseline (P <0.05). The patients treated with HSC+LC showed significantly more improvement in all the above parameters than those treated with LC alone (P <0.05) as well as in sperm motility and the percentage of progressively motile sperm than those treated with HSC alone (P <0.05). The HSC group exhibited remarkable improvement in the above parameters after treatment as compared with the baseline (P <0.05) and higher semen volume and sperm concentration than the LC group (P <0.05). CONCLUSIONS: Huanshao Capsulescombined with levocarnitinedeserves a wide clinical application as a safe and efficacious therapy forasthenospermia, oligospermia,and teratozoospermia.


Subject(s)
Asthenozoospermia/drug therapy , Carnitine/therapeutic use , Drugs, Chinese Herbal/therapeutic use , Oligospermia/drug therapy , Teratozoospermia/drug therapy , Administration, Oral , Capsules , Drug Therapy, Combination , Humans , Male , Semen/drug effects , Semen Analysis , Sperm Count , Sperm Motility
7.
Zhonghua Nan Ke Xue ; 13(2): 185-8, 2007 Feb.
Article in Chinese | MEDLINE | ID: mdl-17345780

ABSTRACT

OBJECTIVE: To explore the correlation between the Traditional Chinese Medicine (TCM) syndrome differentiation and urodynamic parameters in benign prostate hyperplasia (BPH). METHODS: Urodynamic examination was conducted for 152 BPH patients, who were divided by TCM syndrome differentiation into seven types, namely, kidney-yin deficiency, kidney-yang deficiency, aqueduct stagnancy, spleen-qi deficiency, lung-heat and qi stagnancy, wetness-heat down-flow and phlegm-wetness stagnancy. RESULTS: Of the total number of the BPH cases, 71 (46.71%) were differentiated as the type of kidney-yang deficiency, 40 (26.31%) as aqueduct stagnancy, and 14 (9.21%) as kidney-yin deficiency. Fifty-eight cases of Grade III-IV bladder outflow obstruction fell into the type of kidney-yang deficiency, and another 38 cases of the same grade along with 26 cases of Grade V-VI came under the type of aqueduct stagnancy. Of the 12 patients with very weak contractility of detrusor urine, 4 (33.33%) were attributed to the type of kidney-yang deficiency and 7 (58.33%) the type of aqueduct stagnancy. Among the 48 with weak contractility of detrusor urine, 27 (56.25%) fell under the type of kidney-yang deficiency and 17 (35.42%) the type of aqueduct stagnancy. CONCLUSION: The TCM syndrome differentiation of BPH is correlated with bladder outflow obstruction and detrusor urine contractility, which has provided corresponding evidence for the quantization and objectification of the TCM syndrome differentiation of BPH.


Subject(s)
Medicine, Chinese Traditional , Prostatic Hyperplasia/physiopathology , Urodynamics , Aged , Diagnosis, Differential , Humans , Male , Middle Aged , Prostatic Hyperplasia/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...